» Articles » PMID: 36601108

Aryl Hydrocarbon Receptor: The Master Regulator of Immune Responses in Allergic Diseases

Overview
Journal Front Immunol
Date 2023 Jan 5
PMID 36601108
Authors
Affiliations
Soon will be listed here.
Abstract

The aryl hydrocarbon receptor (AhR) is a widely studied ligand-activated cytosolic transcriptional factor that has been associated with the initiation and progression of various diseases, including autoimmune diseases, cancers, metabolic syndromes, and allergies. Generally, AhR responds and binds to environmental toxins/ligands, dietary ligands, and allergens to regulate toxicological, biological, cellular responses. In a canonical signaling manner, activation of AhR is responsible for the increase in cytochrome P450 enzymes which help individuals to degrade and metabolize these environmental toxins and ligands. However, canonical signaling cannot be applied to all the effects mediated by AhR. Recent findings indicate that activation of AhR signaling also interacts with some non-canonical factors like Kruppel-like-factor-6 (KLF6) or estrogen-receptor-alpha (Erα) to affect the expression of downstream genes. Meanwhile, enormous research has been conducted to evaluate the effect of AhR signaling on innate and adaptive immunity. It has been shown that AhR exerts numerous effects on mast cells, B cells, macrophages, antigen-presenting cells (APCs), Th1/Th2 cell balance, Th17, and regulatory T cells, thus, playing a significant role in allergens-induced diseases. This review discussed how AhR mediates immune responses in allergic diseases. Meanwhile, we believe that understanding the role of AhR in immune responses will enhance our knowledge of AhR-mediated immune regulation in allergic diseases. Also, it will help researchers to understand the role of AhR in regulating immune responses in autoimmune diseases, cancers, metabolic syndromes, and infectious diseases.

Citing Articles

Discovery of a novel AhR-CYP1A1 axis activator for mitigating inflammatory diseases using an functional imaging assay.

Zhang F, Zhao B, Fan Y, Qin L, Shi J, Chen L Acta Pharm Sin B. 2025; 15(1):508-525.

PMID: 40041894 PMC: 11873638. DOI: 10.1016/j.apsb.2024.09.014.


Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer.

Rogovskii V, Murugin V, Vorobyev N, Popov S, Sturov N, Krasheninnikov A Front Pharmacol. 2025; 15():1503317.

PMID: 39850551 PMC: 11754188. DOI: 10.3389/fphar.2024.1503317.


Metabolic Side Effects from Antipsychotic Treatment with Clozapine Linked to Aryl Hydrocarbon Receptor (AhR) Activation.

Fehsel K Biomedicines. 2024; 12(10).

PMID: 39457607 PMC: 11505606. DOI: 10.3390/biomedicines12102294.


Predicting phase-I metabolism of piceatannol: an in silico study.

Rajan R, Engels M, Ramanathan M In Silico Pharmacol. 2024; 12(1):52.

PMID: 38854674 PMC: 11153392. DOI: 10.1007/s40203-024-00228-x.


Targeting aryl hydrocarbon receptor to prevent cancer in barrier organs.

Congues F, Wang P, Lee J, Lin D, Shahid A, Xie J Biochem Pharmacol. 2024; 223:116156.

PMID: 38518996 PMC: 11144369. DOI: 10.1016/j.bcp.2024.116156.


References
1.
Yi T, Wang J, Zhu K, Tang Y, Huang S, Shui X . Aryl Hydrocarbon Receptor: A New Player of Pathogenesis and Therapy in Cardiovascular Diseases. Biomed Res Int. 2018; 2018:6058784. PMC: 6015699. DOI: 10.1155/2018/6058784. View

2.
Poulain-Godefroy O, Boute M, Carrard J, Alvarez-Simon D, Tsicopoulos A, de Nadai P . The Aryl Hydrocarbon Receptor in Asthma: Friend or Foe?. Int J Mol Sci. 2020; 21(22). PMC: 7699852. DOI: 10.3390/ijms21228797. View

3.
Bieber T, Kraft S, Geiger E, Wollenberg A, Koch S, Novak N . Fc [correction of Ec] epsilon RI expressing dendritic cells: the missing link in the pathophysiology of atopic dermatitis?. J Dermatol. 2001; 27(11):698-9. DOI: 10.1111/j.1346-8138.2000.tb02261.x. View

4.
. A WAO - ARIA - GALEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organ J. 2020; 13(2):100091. PMC: 7062937. DOI: 10.1016/j.waojou.2019.100091. View

5.
Martin B, Hirota K, Cua D, Stockinger B, Veldhoen M . Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity. 2009; 31(2):321-30. DOI: 10.1016/j.immuni.2009.06.020. View